Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer

Jill M. Kolesar, Marcia Pomplun, Tom Havighurst, Jeanne Stublaski, Barbara Wollmer, Kyung Mann Kim, Joseph A. Tangrea, Howard L. Parnes, Margaret G. House, Jason Gee, Edward Messing, Howard H. Bailey

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background: The isoflavone genistein, a natural soy product with receptor tyrosine kinase-inhibiting activity, as well as phytoestrogenic and other potential anticarcinogenic effects, is being studied as an anticancer agent. Since isoflavones are commonly consumed in food products containing soy proteins, a method to control for baseline isoflavone consumption is needed. Methods: HPLC was used to evaluate baseline plasma and urine concentrations of isoflavone in fifty-four participants with bladder cancer enrolled on a phase II chemoprevention study of G-2535. The soy food frequency questionnaire was used to assess participant's baseline soy intake. The association between baseline isoflavone concentrations and intakes for genistein and daidzein was assessed by the Spearman's rank correlation coefficient. Results: The majority of participants had no detectable genistein or daidzein in plasma at baseline. The median and range of values were 0 (0-1480) nmol/L for genistein, and 0 (0-1260) nmol/L for daidzein. In urine, the median and range of values were 91.0 (0-9030) nmol/L for genistein and 623 (0-100,000) nmol/L for daidzein. The median and range of weekly estimated genistein intake was 0 (0-236) mg/wk; the median and range of weekly estimated daidzein intake was 0 (0-114) mg/wk. There was no relationship to soy intake as measured by the food frequency questionnaire and baseline isoflavone levels in plasma or urine and the Spearman's rank correlation coefficients were not significant. Conclusion: The soy food frequency questionnaire did not correlate with plasma or urine concentrations of either isoflavone. Impact: Alternative methods for controlling for soy consumption, including measuring plasma and urine concentrations, in isoflavone chemoprevention trials should be considered.

Original languageEnglish
Pages (from-to)128-131
Number of pages4
JournalJournal of Oncology Pharmacy Practice
Volume21
Issue number2
DOIs
StatePublished - Apr 15 2014

Bibliographical note

Publisher Copyright:
© The Author(s) 2014.

Funding

This research was supported by a contract from the National Cancer Institute’s Division of Cancer Prevention, a component of the National Institutes of Health in the US Department of Health and Human Services. Supported by the NCI, N01-CN-35153-6 (Phase I and II Clinical Trials of Chemoprevention Agent), Grant M01 RR03186 from the General Clinical Research Centers Program of the National Cancer for Research Resources, National Institutes of Health. This work is supported in part by NIH/NCI P30 CA014520- UW Comprehensive Cancer Center Support Grant.

FundersFunder number
National Institutes of Health (NIH)
U.S. Department of Health and Human Services
National Childhood Cancer Registry – National Cancer InstituteN01-CN-35153-6, M01 RR03186, P30CA014520
National Center for Research Resources

    Keywords

    • Soy food frequency questionnaire
    • chemoprevention
    • isoflavones
    • pharmacokinetics

    ASJC Scopus subject areas

    • Oncology
    • Pharmacology (medical)

    Fingerprint

    Dive into the research topics of 'Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer'. Together they form a unique fingerprint.

    Cite this